EG vs PCRX · P/E 17, rev $8.03B vs P/E 174, rev $369.8M
Everest Group Ltd (EG) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
Everest Group Ltd (EG) is a insurance - reinsurance company listed on US.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EG revenue for 2026-06-30 was $8.03B. Net income was $1.21B. Revenue was up 97.4% from 2026-03-31 to 2026-06-30. EG currently screens at market cap $14.52B and trailing P/E 17.2.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
EG currently screens at market cap $14.52B and trailing P/E 17.2. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the EG and PCRX stock pages for the full models.
Not investment advice.